We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Palla Pharma is a farm products business based in Australia. Palla Pharma shares (PAL) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Palla Pharma has a trailing 12-month revenue of around $16.7 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Long-term investing
| 52-week range | $0.2 - $0.82 |
|---|---|
| 50-day moving average | $0.3396 |
| 200-day moving average | $0.3639 |
| Target price | $1.02 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.43 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.295
| 1 week (2022-01-06) | 0.295 |
|---|---|
| 1 month (2021-12-16) | 0.295 |
| 3 months (2021-10-15) | -1.67% |
| 6 months (2021-07-16) | -24.36% |
| 1 year (2021-01-15) | -56.91% |
|---|---|
| 2 years (2020-01-15) | -68.66% |
| 3 years (2019-01-15) | -74.98% |
| 5 years (2017-01-13) | -89.30% |
Valuing Palla Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Palla Pharma 's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Palla Pharma 's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $49,582 (£26,133).
The EBITDA is a measure of a Palla Pharma 's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $16.7 million |
|---|---|
| Gross profit TTM | $-1,149,682 |
| Return on assets TTM | -32.19% |
| Return on equity TTM | -143.87% |
| Profit margin | 0% |
| Book value | 0.124 |
| Market capitalisation | $47.8 million |
TTM: trailing 12 months
We're not expecting Palla Pharma to pay a dividend over the next 12 months.
Palla Pharma 's shares were split on a 1283:1220 basis on 1 March 2021. So if you had owned 1220 shares the day before before the split, the next day you'd have owned 1283 shares. This wouldn't directly have changed the overall worth of your Palla Pharma shares – just the quantity. However, indirectly, the new 4.9% lower share price could have impacted the market appetite for Palla Pharma shares which in turn could have impacted Palla Pharma 's share price.
Over the last 12 months, Palla Pharma 's shares have ranged in value from as little as $0.2 up to $0.82. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Palla Pharma 's is 1.2174. This would suggest that Palla Pharma 's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Palla Pharma Limited, a vertically integrated pharmaceutical company, produces and distributes narcotic raw materials, active pharmaceutical ingredients, and finished dosage formulations for pharmaceutical markets in Australia and Norway. It also produces and distributes poppy seeds to culinary markets. The company was formerly known as TPI Enterprises Limited and changed its name to Palla Pharma Limited in June 2019. Palla Pharma Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
A fun thriller, an epic sci-fi and a dark teen drama are among our top picks this week.
Australia and England meet for an historic Ashes Test in Hobart.
SPONSORED: Kids are expensive. Here’s how to save money and manage costs when kitting them out for the new school year.
Rapid antigen tests are proving extremely hard to find, but there are options if you can be patient trying to find a RAT.
Some states are delaying the school year while others discuss using rapid antigen tests in classrooms.
You'll fall for these Autumn flight deals on dozens of domestic and international routes.
Despite recent gains, shares in BNPL leader Afterpay are down 20% over the past month.
The 10 biggest movers on the ASX for Friday 14 January 2022.
The Korean-designed KF94 mask may offer greater protection than a cloth mask.
Spoiler alert: The shag cut is still in.
